Please assess the completion status of the following clinical trial:

Trial Title: Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluation~2. Age 18 years or older~3. Body weight ≥ 35 kg~4. Subjects must have histologically or cytologically documented NSCLC who present with locally advanced, unresectable, Stage III disease~5. Subjects must have completed, without progressing, definitive cCRT within 42 days prior to being randomized into the study~6. Provision of tumor tissue sample, when available, from original diagnosis obtained before initiation of chemoradiotherapy~7. Life expectancy ≥ 12 weeks~8. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~9. Subjects must have at least one previously irradiated tumor lesion that can be measured by RECIST v1.1~Main Exclusion Criteria:~1. Mixed small cell and non-small cell lung cancer histology~2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug~3. Prior exposure to any anti-PD1, anti-PD-L1, or anti-CTLA4 antibody for treatment of NSCLC~4. Subjects with history of ≥ Grade 2 pneumonitis from prior chemoradiation therapy~5. Subjects with a history of venous thrombosis within the past 3 months~6. Subjects with history of myocardial infarction, transient ischemic attack, or stroke in the past 6 months~7. Congestive heart failure~8. Active or prior documented autoimmune or inflammatory disorders~9. History of active primary immunodeficiency~10. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~11. History of allogenic organ transplantation~12. QTcF interval ≥ 470 ms~13. History of another primary malignancy~14. Concurrent enrollment in another clinical study \[concurrent enrollment in an observational (non-interventional) clinical study or during the follow-up period of an interventional study is permitted\]~15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Durvalumab monotherapy) (Type: EXPERIMENTAL): durvalumab IV
- Arm A (durvalumab + oleclumab): (Type: EXPERIMENTAL): durvalumab IV and oleclumab IV
- Arm B (durvalumab + monalizumab) (Type: EXPERIMENTAL): durvalumab IV and monalizumab IV

Based on this trial design, predict the completion outcome and termination type (if applicable).